Relative replication fitness of a high-level 3′-azido-3′-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr→Gly) at codon 69

Journal of Virology

Volumn 74, Issue 23, 2000, Pages 10958-10964

  Imamichi, T ^a   Berg, S C ^a   Imamichi, H ^a   Lopez, J C ^a   Metcalf, J A ^a   Falloon, J ^a   Lane, H C ^a  

^a SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS DNA; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ARTICLE; CODON; CONTROLLED STUDY; DNA SEQUENCE; GENE DELETION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; CODON; GENE DELETION; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS REPLICATION; ZIDOVUDINE;

EID: 0034469498     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.23.10958-10964.2000     Document Type: Article

References (45)

1. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone
2. Persistence of azidothymidine-resistant human immunodeficiency virus type 1 RNA genotypes in posttreatment sera
3. Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription
4. 3′-Azido-3′-deoxythymidine (AZT) mediates cross-resistance to nucleoside analogs in the case of AZT-resistant human immunodefieieney virus type 1 variants
5. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme
6. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects
7. Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates
8. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee
9. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
10. Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy
11. Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma
12. Human immunodeficiency virus fitness in vivo: Calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase
13. Broad spectrum of in vivo fitness of human immunodeficiency virus type 1 subpopulations differing at reverse transcriptase codons 41 and 215
14. Reverse transcriptase mutations in sequential HIV-1 isolates in a patient with AIDS
15. Metabolism and anti-human immunodeficiency virus-1 activity of 2-halo-29, 39-dideoxyadenosine derivatives
16. Infection of HTLV-III/ LAV in HTLV-carrying cells MT-2 and MT-4 and application in a plaque assay
17. Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility
18. Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitro
19. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
20. An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 39-azido-39-deoxythymidine
21. High-level resistance to 3′-azido-3′-deoxythymidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1
22. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy
23. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine
24. Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance
25. Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-743Val or Ile and Val-753Leu or Ile) HIV-1 mutants
26. Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an in vitro competitive HIV-1 replication assay
27. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy
28. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)
29. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy
30. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance
31. Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance
32. A mechanism of AZT resistance: An increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase
33. HIV-1 dynamics in vivo: Virion clearance rate, infected cell lifespan, and viral generation time
34. Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy
35. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy
36. Deletions in the beta3-beta4 hairpin loop of HIV-1 reverse transcriptase are observed in HIV-1 isolated from subjects during long-term antiretroviral therapy
37. Mutations in retroviral genes associated with drug resistance: 1999-2000 update
38. Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain
39. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides
40. Viral dynamics in human immunodeficiency virus type 1 infection
41. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors
42. Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: Survey of 787 sequences
43. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites